文献速递前列腺癌

前列腺癌原发EBRT联合或不联合ADT的实践模式

Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-08-31

基于CaPSURE前瞻性社区登记数据库,分析1990至2014年接受原发外照射放疗(EBRT)的1337例局限期前列腺癌患者。结果显示联合ADT的使用率从1990年24%升至1996年60%,2011年降至47%,且接受ADT者诊断时PSA、Gleason分级及CAPRA评分更高,ADT中位疗程4个月。

要点

  • 联合ADT使用率从1990年24%升至1996年60%,2011年降至47%
  • 接受ADT者诊断时PSA更高、Gleason分级更高、CAPRA评分更高
  • ADT中位疗程4个月,临床实践中ADT使用存在较大差异

核心结论

  • 自1990年以来,原发EBRT联合ADT的使用频率和疗程均有所增加。
  • 接受ADT的患者比单纯接受EBRT的患者具有更高危的特征。
  • 临床实践中ADT的使用存在较大差异。

研究设计与样本

  • 基于CaPSURE前瞻性社区疾病登记数据库,纳入14863例前列腺癌患者。
  • 其中1337例为1990至2014年诊断的局限期前列腺癌并接受EBRT作为原发治疗。
  • 采用CAPRA评分评估前列腺癌风险,使用Mantel-Haenszel趋势卡方检验和方差分析比较患者特征。

主要发现

  • 1990至2014年间CaPSURE登记中共14010例诊断为局限期疾病,其中1337例接受EBRT。
  • 接受EBRT患者的中位年龄为71岁。
  • EBRT联合ADT的使用率从1990年24%升至1996年60%,2011年降至47%。
  • 接受ADT的患者诊断时PSA更高、Gleason分级更高、CAPRA评分更高。
  • ADT中位疗程为4个月。

临床怎么用

  • 社区实践中原发EBRT联合ADT的使用率随时间变化,且与更高危特征相关。
  • 临床实践中ADT的使用存在较大差异,提示需关注治疗决策的规范性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen deprivation therapy (ADT) has been shown to improve survival for men with intermediate and high-risk prostate cancer undergoing external-beam radiation therapy (EBRT). Using data from a community-based prospective disease registry, we investigated usage of EBRT with or without neoadjuvant ADT. METHODS: The CaPSURE database contains 14,863 men with prostate cancer, including 1337 men diagnosed between 1990 and 2014 with localized disease who received EBRT as primary treatment. Prostate cancer risk was calculated using the CAPRA score. Patient characteristics were compared using the Mantel-Haenszel chi-square test for trend and analysis of variance. RESULTS: Between 1990 and 2014, 14,010 men were diagnosed with localized disease within the CaPSURE registry. Of those, 1337 underwent EBRT. Patients had a median age of 71 years. The use of ADT in addition to EBRT increased from 24% in 1990 to 60% in 1996 with a decrease seen to 47% in 2011. Men receiving ADT have differing clinical characteristics including higher PSA at diagnosis, higher Gleason grade, and higher CAPRA scores. Median ADT duration was 4 months. CONCLUSIONS: The use of ADT in conjunction with primary EBRT has increased in frequency and duration since 1990. Men receiving ADT have higher risk characteristics than those receiving EBRT alone. There is substantial variability in use of ADT in clinical practice.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Schmidt B, Eapen RS, Cowan JE, et al. Practice patterns of primary EBRT with and without ADT in prostate cancer treatment. Prostate Cancer Prostatic Dis. 2018. PMID: 30171230. doi:10.1038/s41391-018-0084-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。